MetaVia and Syntekabio Collaborate on AI-Driven Drug Discovery

Aug 4, 2025
MetaVia Inc. has announced a collaboration with Syntekabio to explore new indications for its oral GPR119 agonist, DA-1241, using AI technology.
MetaVia and Syntekabio Collaborate on AI-Driven Drug Discovery

MetaVia Inc. has announced a research collaboration with Syntekabio to explore additional indications for DA-1241, its novel oral GPR119 agonist, announced in a press release. This partnership aims to leverage Syntekabio's DeepMatcher® AI platform to identify new disease targets and optimize the therapeutic profile of DA-1241.

The collaboration follows positive results from MetaVia's Phase 2a study of DA-1241, which showed favorable safety and tolerability, along with hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). By utilizing Syntekabio's AI-driven compound-protein interaction prediction platform, the companies plan to conduct large-scale virtual screenings against over 1,700 validated protein targets to uncover new, high-potential indications.

MetaVia's DA-1241 has shown potential as a standalone or combination therapy for MASH and type 2 diabetes, promoting the release of key gut peptides that play roles in glucose and lipid metabolism. The collaboration is expected to accelerate the discovery process and maximize the therapeutic value of DA-1241, with initial insights anticipated later this year.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.